Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease.
Sotzny, Franziska, Blanco, Julià, Capelli, Enrica et al. · Autoimmunity reviews · 2018 · DOI
Quick Summary
This review examines evidence that ME/CFS may be caused by the immune system attacking the body (autoimmune disease). Researchers found that people with ME/CFS have unusual immune patterns, including abnormal antibodies and changes in immune cells. Importantly, a treatment that removes certain immune cells (rituximab) helped about half of ME/CFS patients in clinical trials, suggesting an autoimmune mechanism in at least some people.
Why It Matters
This review consolidates growing evidence that autoimmunity plays a significant role in at least some ME/CFS cases, moving the field beyond purely infectious or behavioral explanations. The clinical response to B-cell depleting therapy provides tangible proof-of-concept that immune-targeted interventions can benefit ME/CFS patients, potentially opening pathways to more effective, mechanism-based treatments.
Observed Findings
Immune dysregulation documented in ME/CFS including abnormal cytokine profiles and immunoglobulin levels
Reduced natural killer cell cytotoxicity in ME/CFS patients
Identification of autoantibodies against neurotransmitter receptors in ME/CFS individuals
B-cell depletion with rituximab produced clinical benefits in approximately 50% of ME/CFS patients in Norwegian trials
Evidence for severe metabolic disturbances potentially mediated by serum autoantibodies
Inferred Conclusions
At least a subset of ME/CFS patients has autoimmune etiology, distinct from other disease mechanisms
Autoantibodies, particularly those targeting neurotransmitter receptors, likely contribute to ME/CFS pathophysiology
B-cell targeting therapy may be a viable treatment approach for autoimmune-mediated ME/CFS
Further characterization of autoantibodies and their role in disease onset is essential for improving diagnosis and treatment strategies
Remaining Questions
Which patient characteristics or biomarkers identify those with autoimmune-mediated ME/CFS versus other disease mechanisms?
What This Study Does Not Prove
This review does not establish that autoimmunity causes ME/CFS in all patients—it identifies autoimmune mechanisms in a subset. The review does not prove causation from correlational immunological findings, nor does it explain why only some patients respond to rituximab or identify which patient characteristics predict autoimmune versus other disease mechanisms. Long-term treatment efficacy and optimal patient selection criteria remain unresolved.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.